Study of Acalabrutinib and Tafasitamab in MZL Patients (Q113897307)
Jump to navigation
Jump to search
clinical trial
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Study of Acalabrutinib and Tafasitamab in MZL Patients |
clinical trial |
Statements
Phase II Trial of Acalabrutinib in Combination With Tafasitamab in Patients With Previously Treated Marginal Zone Lymphomas (MZL) (English)
0 references
20 October 2021
0 references
15 September 2027
0 references
24
0 references
18 year
0 references